Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.50 |
| ▸ | FAP | Q12884 | 9/20 | 0.50 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.49 |
| ▸ | GHSR | Q92847 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19154499 | 0.93 | DPP4 (0.48) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL196984 | 0.90 | DPP4 (0.61) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL29801450 | 0.90 | DPP4 (0.61) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL12650019 | 0.88 | DPP4 (0.51) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL13955072 | 0.87 | MAPT (0.39) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL24508490 | 0.87 | DPP4 (0.51) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL10030473 | 0.86 | DPP4 (0.50) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL13954913 | 0.86 | DPP4 (0.50) | DPP4FAPPOU2F2ADORA3CHRM1 | |
| SCHEMBL13955108 | 0.84 | ALDH1A1 (0.42) | ADORA3ALDH1A1MAPTTSHRMAPK1 | |
| SCHEMBL24743925 | 0.82 | DPP4 (0.61) | DPP4FAPPOU2F2ADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9713618-B2 | Method for modifying food intake and regulating food preference with a DPP-4 inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-07-25 | — | — | US | disclosed |
| US-8232281-B2 | Uses of DPP-IV inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20120165251-A1 | Diabetes therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20120094894-A1 | ANTIDIABETIC MEDICATIONS COMPRISING A DPP-4 INHIBITOR (LINAGLIPTIN) OPTIONALLY IN COMBINATION WITH OTHER ANTIDIABETICS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20120003313-A1 | DPP IV INHIBITOR FORMULATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20110301182-A1 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110206766-A1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-25 | — | — | US | disclosed |
| US-20110098240-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | US | disclosed |
| US-20110092510-A1 | DPP-IV INHIBITORS FOR USE IN THE TREATMENT OF NAFLD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110065731-A1 | USES OF DPP-IV INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-17 | — | — | US | disclosed |
| US-7495002-B2 | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-24 | — | — | US | disclosed |
| US-20070281940-A1 | USES OF DPP-IV INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094894-A1 | ANTIDIABETIC MEDICATIONS COMPRISING A DPP-4 INHIBITOR (LINAGLIPTIN) OPTIONALLY IN COMBINATION WITH OTHER ANTIDIABETICS | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 110/4885POU2F2 3816/4885 |
| US-20110092510-A1 | DPP-IV INHIBITORS FOR USE IN THE TREATMENT OF NAFLD | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 25/4885POU2F2 3277/4885 |
| US-20070281940-A1 | USES OF DPP-IV INHIBITORS | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 13/4885POU2F2 3160/4885 |
| US-20120165251-A1 | Diabetes therapy | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 113/4885POU2F2 2348/4885 |
| US-20110065731-A1 | USES OF DPP-IV INHIBITORS | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 13/4885POU2F2 3160/4885 |
| US-20110206766-A1 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 27/4885POU2F2 3328/4885 |
| US-20110301182-A1 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 134/4885POU2F2 981/4885 |
| US-20110098240-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR | SLC5A1, SLC5A2, DPP4 | DPP4 3/4885FAP 413/4885POU2F2 2807/4885 |
| US-20120003313-A1 | DPP IV INHIBITOR FORMULATIONS | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 26/4885POU2F2 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.